Publications
(Selected from more than 90 total.)
1. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-739.
2. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzales C, McMahon D, Jonas L, Meibohm A, Holder D, Schleif WA, Condra JH, Emini EA, Isaacs R, Chodakewitz JA, Richman DD. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100 week follow-up. JAMA 1998;280:35-41.
3. Gulick RM, McAuliffe V, Holden-Wiltse J, Crumpacker C, Liebes L, Stein DS, Meehan P, Hussey S, Forcht J, Valentine FT. Phase I studies of hypericin, the active compound in St. John#146;s Wort, as an antiretroviral agent in HIV infected adults: AIDS Clinical Trials Group Protocols 150 258. Ann Intern Med 1999;130:510-514.
4. Murphy RL, Gulick RM, DeGruttola V, D#146;Aquila RT, Eron JJ, Sommadossi J-P, Currier JS, Smeaton L, Frank I, Caliendo AM, Gerber JG, Tung R, Kuritzkes DR. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. J Infect Dis 1999;179:808-816.
5. Gulick RM, Mellors JW, Havlir D, Eron JJ, Meibohm A, Condra JH, Valentine FT, McMahon D, Gonzalez C, Jonas L, Emini E, Chodakewitz J, Isaacs R, Richman DD. Suppression of HIV viremia for 3 years with indinavir, zidovudine, and lamivudine. Ann Intern Med 2000;133:35-39.
6. Gulick RM, Hu XJ, Fiscus SA, Fletcher CV, Haubrich R, Cheng H, Acosta E, Lagakos S, Snyder S, Fischl M, Pettinelli C, Katzenstein D. Saquinavir in combination with ritonavir or nelfinavir together with delavirdine, adefovir dipivoxil, or both in HIV-infected subjects with virologic failure on indinavir -- ACTG 359. J Infect Dis 2000;182:1375-1384.
7. Gulick RM, Smeaton LM, D#146;Aquila RT, Eron JJ, Currier JS, Gerber JG, Sommadossi J-P, Tung R, Snyder S, Kuritzkes DR, Murphy RL. Indinavir, nevirapine, stavudine and lamivudine for HIV-infected, amprenavir-experienced subjects: ACTG Protocol 373. J Infect Dis 2001;183:715-721.
8. Gulick RM, Hu J, Fiscus SA, Fletcher CV, Haubrich R, Cheng H, Acosta E, Lagakos SW, Swanstrom R, Freimuth W, Snyder S, Mills C, Fischl M, Pettinelli C, Katzenstein D. Durability of response to treatment for antiretroviral-experienced subjects: 48 week results from AIDS Clinical Trials Group Study 359. J Infect Dis 2002;186:626-633.
9. Gulick RM, Meibohm A, Havlir D, Eron JJ, Mosley A, Chodakewitz JA, Isaacs R, Gonzalez C, McMahon D, Richman DD, Robertson M, Mellors JW. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS 2003;17:2345-9.
10. Eron JJ, Gulick RM, Bartlett JA, Merigan T, Arduino R, Kilby JM, Yangco B, Diers A, Drobnes C, DeMasi R, Greeenberg M, Melby T, Raskino C, Rusnak P, Zhang Y, Spence R, Miralles GD. Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. J Infect Dis 2004;189:1075-1083.
11. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL, Kuritzkes DR. Triple nucleoside analogue vs. efavirenz-containing regimens for the initial treatment of HIV-1 infection: AIDS Clinical Trials Group (ACTG) Study A5095. N Engl J Med 2004;350:1850-61.
12. Swanstrom R, Bosch RJ, Katzenstein D, Cheng H, Jiang H, Hellman N, Haubrich R, Fiscus SA, Fletcher CV, Acosta EP, Gulick RM. Weighted phenotypic susceptibility scores (PSS) are predictive of HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects. J Infect Dis 2004;190:886-893.
13. Fletcher CV, Testa MA, Brundage RC, Chesney MA, Haubrich R, Acosta EP, Martinez A, Jiang H, Gulick RM. Four measures of antiretroviral medication adherence and virologic response in AIDS Clinical Trials Group (ACTG) study 359. J Acquir Immune Defic Syndr 2005;40;301-306.
14. Clifford DB, Evans S, Yang Y, Acosta EP, Goodkin K, Tashima K, Simpson D, Dorfman D, Ribaudo H, Gulick RM. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). Ann Intern Med 2005;143:714-721.
15. Severe P, Leger P, Charles M, Noel F, Bonhomme G, Bois G, George E, Kenel-Pierre S, Wright P, Gulick R, Johnson WD, Pape JW, Fitzgerald DW. Antiretroviral therapy in a 1000 patients with AIDS in Haiti. N Engl J Med 2005;353:2325-2334.
16. Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer III WA, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, Klingman KL, Kuritzkes DR. Three- vs. four-drug antiretroviral regimen for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 2006:296:769-781.
17. Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, Coakley E, Greaves W, Godfrey C, Skolnik PR, Timpone J, Rodriguez B, Gulick RM. HIV Type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group 5211. Clin Infect Dis 2007;44:591-595.
18. Kuritzkes DR, Ribaudo HJ, Squires KE, Koletar SL, Santana J, Riddler SA, Reichman R, Shikuma C, Meyer WA, Klingman K, Gulick RM. Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or rfavirenz-containing regimens: ACTG A5166s. J Infect Dis 2007;195:1169-1176.
19. Gulick RM, Lalama CM, Ribaudo HJ, Shikuma CM, Schackman BR, Schouten J, Squires KE, Koletar SL, Pilcher CD, Reichman RC, Klingman KL, Kuritzkes DR. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virologic suppression. AIDS 2007;21:813-823.
20. Gulick RM, Su Z, Flexner C, Hughes MD, Skolnik PR, Wilkin TJ, Gross R, Krambrink A, Coakley E, Greaves WL, Zolopa A, Reichman R, Godfrey C, Hirsch M, Kuritzkes DR. Phase II study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: ACTG 5211. J Infect Dis 2007;196:304-312.
21. Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RM. Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: Results of ACTG A5095. J Acquir Immune Defic Syndr 2007;46:547-554.
22. Kuritzkes DR, Lalama CM, Ribaudo HJ, Marcial M, Meyer WA, Shikuma C, Johnson VA, Fiscus S, D’Aquila RT, Schackman BR, Acosta EP, Gulick RM. Pre-existing non-nucleoside reverse transcriptase inhibitor resistance predicts virologic failure of an efavirenz-based regimen in treatment-naïve HIV-1-infected subjects. J Infect Dis 2008;197:867-870.
23. Ribaudo HJ, Kuritzkes DR, Lalama CM, Schouten JT, Schackman BR, Acosta EP, Gulick RM. Activity of efavirenz-based regimens in treatment-naïve patients across a range of pre-treatment HIV-1 RNA level and CD4 cell counts: ACTG A5095. J Infect Dis 2008;197:1006-1010.
24. Anderson JA, Jiang H, Ding X, Petch L,Journigan T,Fiscus SA,Haubrich R, Katzenstein D, Swanstrom R, Gulick RM. Genotypic susceptibility scores and HIV-1 RNA responses in treatment experienced subjects with HIV-1 infection. AIDS Res Hum Retroviruses 2008;24:685-694.
25. Tsibris AMN, Sagar M, Gulick RM, Su Z, Hughes M, Greaves W, Subramanian M, Flexner C, Giguel F, Leopold KE, Coakley E, Kuritzkes DR. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol 2008;82:8210-8214.
26. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Duune MW, van der Ryst E, Mayer H. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429-41.
27. Chan-Tack KM, Struble KA, Morgensztejn N, Murray JS, Gulick R, Cheng B, Weller I, Miller V. HIV clinical trial design for antiretroviral development: moving forward. AIDS 2008;22:2419-2427.
28. Charles M, Noel F, Leger P, Severe P, Riviere C, Beauharnais CA, Miller E, Rutledge J, Bang H, Shealey W, D’Aquila RT, Gulick RM, Johnson WD, Wright PF, Pape JW, Fitzgerald DW. Antiretroviral therapy for HIV-1 infected adolescents and youth aged 13-25 years in Haiti. Bull World Health Organ 2008 (in press).
29. Tsibris AMN, Paredes R, Chadburn A, Su Z, Henrich T, Krambrink A, Hughes M, Aberg JA, Tashima K, Currier JS, Godfrey C, Greaves W, Flexner C, Skolnik PR, Wilkin T, Gulick RM, Kuritzkes DR. Lymphoma Diagnoses and EBV Plasma Viral Loads during Vicriviroc Therapy: Results from ACTG 5211. Clin Infect Dis 2008 (in press).
